Commonwealth Equity Services
ADAP

Commonwealth Equity Services’s Adaptimmune Therapeutics ADAP Stock Holding History

Commonwealth Equity Services’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,433
Closed -$13K – 4087
2024
Q3 		$13K Sell
13,433
-6,762
-33% -$7.67K ﹤0.01% 4022
2024
Q2 		$20K Buy
20,195
+3,849
+24% +$4.22K ﹤0.01% 3969
2024
Q1 		$26K Sell
16,346
-412
-2% -$497 ﹤0.01% 3944
2023
Q4 		$13K Sell
16,758
-15,117
-47% -$8.52K ﹤0.01% 3845
2023
Q3 		$25K Hold
31,875
– – ﹤0.01% 3716
2023
Q2 		$29K Buy
+31,875
New +$38K ﹤0.01% 3721
2020
Q3 		– Sell
-28,500
Closed -$285K – 3047
2020
Q2 		$285K Buy
+28,500
New +$179K ﹤0.01% 2310

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Commonwealth Equity Services's ADAP Position: Q4 2024 in Review

Commonwealth Equity Services sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 13,433 shares — an estimated $13K sold.

Commonwealth Equity Services first reported a position in ADAP in Q2 2020 and held it in 7 quarters. The position peaked at $285K in Q2 2020. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • Commonwealth Equity Services reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 13,433 Adaptimmune Therapeutics shares in Q4 2024, an estimated $13K.
  • Commonwealth Equity Services first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 7 quarters.
  • Commonwealth Equity Services's Adaptimmune Therapeutics position peaked at $285K in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Commonwealth Equity Services's 13F filing for Q4 2024, filed 10 Feb 2025.